<DOC>
	<DOCNO>NCT01965652</DOCNO>
	<brief_summary>The purpose study evaluate long-term safety naldemedine treatment constipation due opioid therapy .</brief_summary>
	<brief_title>Long Term Safety Naldemedine</brief_title>
	<detailed_description>This Phase 3 , multi-center , randomize double-blind , placebo control , parallel-group study design evaluate long term safety naldemedine compare placebo treatment opioid-induced constipation ( OIC ) subject non-malignant chronic pain receive opioid therapy .</detailed_description>
	<mesh_term>Constipation</mesh_term>
	<criteria>Inclusion Criteria 1 . Subjects age 18 80 year inclusive time inform consent 2 . Subjects must nonmalignant chronic pain treat must opioid induced constipation ( OIC ) 3 . Subjects must treat stable opioid regimen total daily dose average â‰¥ 30 mg equivalent oral morphine sulfate 4 . Subjects may may routine laxative regimen time Screening Exclusion Criteria 1 . Evidence significant structural abnormality gastrointestinal ( GI ) tract 2 . Evidence active medical disease affect bowel transit 3 . History pelvic disorder may cause constipation 4 . Surgery ( except minor procedure ) within 60 day Screening 5 . History chronic constipation prior start analgesic medication potential nonopioid cause bowel dysfunction may major contributor constipation ( e.g . mechanical GI obstruction ) 6 . Subjects never take laxatives treatment OIC 7 . Current use prohibit medication include opioid antagonist , partial mixed agonists/antagonists</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Opioid Induced Constipation</keyword>
</DOC>